Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study

Table 1 Baseline Demographic and Treatment Characteristics

	RT only (N = 494)		RT + ADT (N = 1446)		p
	No.	%	No.	%	p
Age at start of treatment, years
Median (range)	68 (49–94)		71 (46–89)		< 0.001
Below 70	274	55.5	650	45.0	< 0.001
70 & over	220	44.5	796	55.0
Ethnic group					0.677
Chinese	447	90.5	1297	89.7
Malays	17	3.4	66	4.6
Indians	20	4.0	50	3.5
Others	10	2.0	33	2.3
ECOG performance status					0.024
0–1	493	99.8	1425	98.5
2–4	1	0.2	21	1.5
Gleason score					< 0.001
6 or less	241	48.8	177	12.2
7	197	39.9	770	53.3
8–10	39	7.9	485	33.5
Missing	17	3.4	14	1.0
ISUP grade					< 0.001
1	241	48.8	177	12.2
2	136	27.5	451	31.2
3	61	12.3	319	22.1
4	23	4.7	207	14.3
5	16	3.2	278	19.2
Missing	17	3.4	14	1.0
D’Amico risk classification					< 0.001
Low	174	35.2	49	3.4
Intermediate	198	40.1	419	29.0
High	107	21.7	973	67.3
Missing	15	3.0	5	0.3
Radiation intent					< 0.001
Definitive radiation	354	71.7	1348	93.2
Salvage radiation	140	28.3	98	6.8
ADT type^a					NA
Agonist	NA	NA	1401	96.9
Antagonist	NA	NA	45	3.1
ADT duration					NA
4–6 months	NA	NA	557	38.5
> 6 months	NA	NA	889	61.5
Baseline CVD risk factor					0.010
At least one	386	78.1	1209	83.6
None	83	16.8	196	13.6
Missing	25	5.1	41	2.8
Previous history of MACE					0.127
No	398	80.6	1113	77.0
Yes	95	19.2	332	23.0
Missing	1	0.2	1	0.1

ECOG Eastern Cooperative Oncology Group, ISUP International Society of Urological Pathology, CVD Cardiovascular disease, NA Not applicable
^aAgonist included goserelin, leuprorelin & triptorelin; antagonist included degarelix

ISSN: 2057-3804